Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777469

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777469

Precision Oncology

PUBLISHED:
PAGES: 382 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Precision Oncology Market to Reach US$171.7 Billion by 2030

The global market for Precision Oncology estimated at US$112.3 Billion in the year 2024, is expected to reach US$171.7 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Precision Oncology Therapeutics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$121.9 Billion by the end of the analysis period. Growth in the Precision Oncology Diagnostics segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.6 Billion While China is Forecast to Grow at 11.7% CAGR

The Precision Oncology market in the U.S. is estimated at US$30.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$36.6 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Precision Oncology Market - Key Trends & Drivers Summarized

How Is Precision Oncology Transforming Cancer Treatment and Patient Outcomes?

Precision oncology is redefining cancer treatment by leveraging genetic profiling, molecular diagnostics, and targeted therapies to create personalized treatment plans for patients. Unlike traditional one-size-fits-all approaches, precision oncology tailors treatment based on an individual’s genetic mutations, tumor biomarkers, and immune system response. Advances in next-generation sequencing (NGS) and liquid biopsy technologies have enabled oncologists to detect cancer-related genetic alterations early, allowing for more effective intervention strategies. Pharmaceutical companies are increasingly investing in precision medicine-driven drug development, leading to the rise of targeted therapies such as monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapies that improve treatment efficacy while reducing adverse effects. Additionally, AI-powered analytics and big data platforms are accelerating biomarker discovery, enabling the development of more precise diagnostic tools. As the oncology landscape shifts toward molecularly guided treatment strategies, precision oncology is emerging as a leading force in cancer care, offering patients more personalized and effective treatment options.

What Challenges Are Limiting the Widespread Adoption of Precision Oncology?

Despite its revolutionary potential, precision oncology faces several challenges that hinder its broad adoption in clinical practice. One of the most significant barriers is the high cost of genomic testing and targeted therapies, making them inaccessible to many patients and healthcare systems. The complexity of integrating molecular diagnostics into standard oncology workflows also poses a challenge, as many healthcare providers require specialized training to interpret genetic data effectively. Additionally, regulatory hurdles and lengthy approval processes for targeted therapies slow down market entry, delaying patient access to cutting-edge treatments. Limited availability of high-quality patient data and the need for large-scale clinical trials further complicate the development of precision oncology treatments. Ethical concerns surrounding genetic data privacy and the potential for insurance discrimination also raise concerns among patients. Addressing these challenges will require continued investment in affordable genomic testing, healthcare provider education, regulatory reforms, and stronger patient data protection policies.

How Are Innovations and Digital Technologies Enhancing the Future of Precision Oncology?

Technological advancements in genomics, artificial intelligence, and bioinformatics are accelerating the evolution of precision oncology, improving diagnostic accuracy and treatment efficacy. AI-driven algorithms are enhancing the interpretation of complex genetic datasets, allowing oncologists to identify actionable mutations more efficiently. The integration of liquid biopsy technology is providing non-invasive methods for detecting circulating tumor DNA (ctDNA), enabling real-time monitoring of tumor progression and treatment response. Immunotherapy advancements, including personalized cancer vaccines and adoptive T-cell therapies, are further expanding precision oncology’s capabilities in targeting specific cancer subtypes. Additionally, blockchain technology is being explored to ensure secure and transparent sharing of patient genomic data, improving collaboration between researchers and healthcare providers. The rise of decentralized clinical trials and real-world evidence (RWE) is also contributing to precision oncology’s growth, facilitating faster drug development and regulatory approvals. As digital technologies continue to refine precision oncology approaches, the field is set to become more accessible, cost-effective, and integrated into mainstream cancer treatment.

What Is Driving the Growth of the Precision Oncology Market?

The growth in the precision oncology market is driven by several factors, including the increasing prevalence of cancer, rising demand for personalized treatment solutions, and continuous advancements in genomics and molecular diagnostics. The rapid expansion of companion diagnostics is fueling the market, as pharmaceutical companies develop targeted therapies that require biomarker-based patient stratification. Government initiatives supporting precision medicine research and funding for genomic sequencing programs are further accelerating market growth. The increasing role of AI and machine learning in oncology research is also enhancing drug discovery and patient management, improving treatment outcomes. Additionally, the expansion of precision oncology services into emerging markets, coupled with rising healthcare expenditure, is creating new growth opportunities. As healthcare systems worldwide shift toward precision-driven cancer care, the precision oncology market is expected to witness sustained expansion, shaping the future of cancer diagnosis and treatment.

SCOPE OF STUDY:

The report analyzes the Precision Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Precision Oncology Therapeutics, Precision Oncology Diagnostics); Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Other Cancer Types); End-Use (Hospitals & Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • BioNTech SE
  • Bristol Myers Squibb
  • Caris Life Sciences
  • Eli Lilly and Company
  • Exact Sciences Corporation
  • Foundation Medicine
  • Gilead Sciences
  • Guardant Health
  • Illumina, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NeoGenomics Laboratories
  • Novartis
  • Pfizer Inc.
  • Qiagen
  • Roche Diagnostics
  • Tempus AI, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP32669

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Precision Oncology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rapid Expansion of Genomic Sequencing Capabilities Drives Adoption of Targeted Cancer Therapies
    • Integration of AI-Powered Predictive Analytics Strengthens Business Case for Personalized Oncology Care
    • Advancements in Liquid Biopsy Technologies Propel Growth in Early Detection and Minimal Residual Disease Monitoring
    • Rising Incidence of Cancer Worldwide Throws the Spotlight on Demand for Individualized Treatment Protocols
    • Increasing Availability of Tumor-Specific Biomarkers Expands Addressable Market Opportunity for Precision Drugs
    • Collaborations Between Pharma and Diagnostic Firms Accelerate Development of Companion Diagnostics
    • Growing Reimbursement Support for Genomic Testing Drives Utilization of Precision Oncology Solutions
    • Next-Generation Sequencing (NGS) Cost Decline Spurs Growth in Clinical Adoption Across Oncology Practices
    • Emergence of Multi-Cancer Early Detection (MCED) Tests Creates New Frontiers in Personalized Oncology
    • Personalized Immunotherapy Advancements Generate Demand for Mutation-Driven Therapy Development
    • Rise in Clinical Trials for Basket and Umbrella Studies Strengthens Evidence Base for Tumor-Agnostic Therapies
    • Integration of Real-World Evidence Platforms Drives Longitudinal Monitoring and Outcome-Based Treatment Models
    • Growing Focus on Molecular Tumor Boards Enhances Decision Support for Individualized Cancer Treatment
    • Expanding Role of Digital Pathology and AI Imaging Tools Drives Precision Diagnostics in Oncology
    • Shift Toward Value-Based Healthcare Models Strengthens Justification for Personalized Cancer Therapy Adoption
    • Global Expansion of Cancer Genomics Research Initiatives Spurs Innovation in Biomarker-Driven Therapies
    • Increasing Demand for Minimal Toxicity Therapies Accelerates Adoption of Tumor-Specific Targeted Treatments
    • Development of Patient Stratification Algorithms Enhances Efficacy of Precision Treatment Matching
    • Regulatory Approvals of Tumor-Agnostic Drugs Strengthen Market Confidence in Cross-Cancer Applications
    • Growing Integration of Polygenic Risk Scores in Oncology Risk Assessment Expands Preventive Care Opportunities
    • Advances in Synthetic Biology and CRISPR Technologies Drive Innovation in Tumor-Specific Therapeutic Platforms
    • Challenges in Data Interoperability and Genomic Data Integration Create Barriers to Scalable Precision Oncology Deployment
    • Expansion of Personalized Cancer Vaccines and Neoantigen-Based Therapies Opens New Therapeutic Avenues
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Precision Oncology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Precision Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Precision Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Precision Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Precision Oncology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Precision Oncology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Precision Oncology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Precision Oncology Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Precision Oncology Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Precision Oncology Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Healthcare Data Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Healthcare Data Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Healthcare Data Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals & Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals & Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • CHINA
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Precision Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Precision Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Precision Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Precision Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Precision Oncology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • INDIA
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Precision Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Precision Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Precision Oncology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Precision Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Precision Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Precision Oncology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Precision Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Precision Oncology by Type - Precision Oncology Therapeutics and Precision Oncology Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Precision Oncology by Type - Percentage Breakdown of Value Sales for Precision Oncology Therapeutics and Precision Oncology Diagnostics for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Precision Oncology by End-Use - Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Precision Oncology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Healthcare Data Companies End-Use and Hospitals & Diagnostic Laboratories End-Use for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Precision Oncology by Cancer Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Precision Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!